Clinical Trials Logo

Pulmonary Eosinophilia clinical trials

View clinical trials related to Pulmonary Eosinophilia.

Filter by:

NCT ID: NCT04184284 Completed - Asthma Clinical Trials

Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions

imPROve
Start date: November 15, 2019
Phase:
Study type: Observational [Patient Registry]

The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary care setting in Germany. The study also aims to investigate Quality-of-Life (QoL), the early treatment response, treatment effectiveness and the change in asthma control over time, following benralizumab therapy. This study will also describe the physician-chosen reasons for starting beralizumab therapy or switching to benralizumab therapy.

NCT ID: NCT04181190 Completed - Asthma Clinical Trials

Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients

BIONIGE
Start date: October 11, 2019
Phase:
Study type: Observational

Real-life, observational, retrospective, multicenter study to evaluate the effects of anti-IL5 biological treatments on blood total IgE Levels in atopic patients with severe eosinophilic asthma.

NCT ID: NCT04159519 Completed - Asthma Clinical Trials

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Start date: July 27, 2020
Phase: Phase 4
Study type: Interventional

This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.

NCT ID: NCT04126499 Completed - Clinical trials for Severe Eosinophilic Asthma

Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain

ORBE
Start date: January 13, 2020
Phase:
Study type: Observational

Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of the investigator were candidates to receive benralizumab in the individualized access program approved by national health authorities. Primary Objective: To describe the demographic and baseline characteristics in patients with severe eosinophilic asthma who participated in the individualized access program approved in Spain and received at least one dose of benralizumab. Secondary Objectives: To describe clinical outcomes in severe eosinophilic asthma patients who received at least three doses of benralizumab in the individualized access program.

NCT ID: NCT04046939 Completed - Asthma Clinical Trials

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

EXHALE-1
Start date: August 15, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

NCT ID: NCT03976310 Completed - Asthma Clinical Trials

CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients

BenraliScan
Start date: June 20, 2019
Phase: N/A
Study type: Interventional

BenraliScan aims to obtain thoracic computed tomography imaging data to predict the future level of patient response to a monoclonal antibody. Because the clinical responses under study can take many months to manifest, early identification of patients most-likely to benefit from treatment and treatment rule-out for others will save considerable time for everybody involved. The primary objective of BenraliScan is to determine the prognostic value (sensitivity, specificity, positive predictive value, negative predictive value) of air-trapping measures (Expiratory/Inspiratory ratios for Mean Lung Density (MLDe/i)) detected via quantitative thoracic computed tomography at baseline for improvement in exacerbation rate (the presence of a ≥50% reduction in baseline exacerbation rate versus the absence of a ≥50% reduction in baseline exacerbation rate) at 52 weeks among eosinophilic asthma patients treated with Benralizumab.

NCT ID: NCT03907137 Completed - Clinical trials for Severe Eosinophilic Asthma

Real World Study With Benralizumab in Severe Asthma in Switzerland

BEEPS
Start date: January 21, 2019
Phase:
Study type: Observational

BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1 to 16 weeks post-treatment initiation including use of OCS. The generated data on the time of asthma symptom relief after initiation of benralizumab will support patient management for a better disease control in severe asthma patients under benralizumab treatment. To assess long term outcomes the patients will have a last mandatory visit after 56 weeks, with no visits scheduled between week 16 and 56.

NCT ID: NCT03696914 Completed - Asthma Clinical Trials

Intense Airway Eosinophilia in Asthma

Start date: June 6, 2017
Phase:
Study type: Observational

In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes. Of these, one of the most common is eosinophilic asthma, based on induced sputum differential cell count. Patients with severe asthma and an eosinophilic asthma phenotype have different pathophysiological characteristics than those seen in patients with with mild asthma. However, few studies have compared patients with eosinophilic phenotype according to the severity of asthma. In addition, the stability of the phenotype based on the sputum results has been criticized. This study aims to describe the characteristics of patients with eosinophilic asthma phenotype according to the severity of asthma and determine the stability of the phenotype.

NCT ID: NCT03563521 Completed - Clinical trials for Chronic Rhinosinusitis (Diagnosis)

Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma

Start date: November 27, 2017
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to determine and compare serum cytokine levels of six different severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia and/or chronic rhinosinusitis and/or nasal polyposis status.

NCT ID: NCT03470311 Completed - Clinical trials for Severe Prednisone Dependent Eosinophilic Asthma

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

Start date: April 26, 2018
Phase: Phase 3
Study type: Interventional

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control